Joseph Q. Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joseph Q. Lu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Adam Tully Waickman
Department of Microbiology and Immunology, SUNY Upstate Medical University
1 shared publication - Chad Gebo
Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, USA
1 shared publication - Heather Friberg
Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
1 shared publication HengSheng Fang
Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, USA
1 shared publicationJeffrey R. Currier
Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, USA
1 shared publicationKrista Newell
Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, USA
1 shared publication
Latest Publications
- 1 April 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (5) , 1356-1367
Low-dose dengue virus 3 human challenge model: a phase 1 open-label study
Dengue human infection models present an opportunity to explore the potential of a vaccine, anti-viral or immuno-compound for clinical benefit in a controlled setting. Here we report the outcome of a phase 1 open-label assessment of a low-dose dengue virus 3 (DENV-3) challenge model (NCT04298138), in which nine participants received a subcutaneous inoculation with 0.5 ml of a 1.4 × 103 plaque-forming unit per ml suspension of the attenuated DENV-3 strain CH53489. The primary and secondary endpoints of the study were to assess the safety of this DENV-3 strain in healthy flavivirus-seronegative individuals. All participants developed RNAaemia within 7 days after inoculation with peak titre ranging from 3.13 × 104 to 7.02 × 108 genome equivalents per ml. Solicited symptoms such as fever and rash, clinical laboratory abnormalities such as lymphopenia and thrombocytopenia, and self-reported symptoms such as myalgia were consistent with mild-to-moderate dengue in all volunteers. DENV-3-specific seroconversion and memory T cell responses were observed within 14 days after inoculation as assessed by enzyme-linked immunosorbent assay and interferon-gamma-based enzyme-linked immunospot. RNA sequencing and serum cytokine analysis revealed anti-viral responses that overlapped with the period of viraemia. The magnitude and frequency of clinical and immunologic endpoints correlated with an individual’s peak viral titre.
- 1 April 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (5) , 1356-1367
Low-dose dengue virus 3 human challenge model: a phase 1 open-label study
Dengue human infection models present an opportunity to explore the potential of a vaccine, anti-viral or immuno-compound for clinical benefit in a controlled setting. Here we report the outcome of a phase 1 open-label assessment of a low-dose dengue virus 3 (DENV-3) challenge model (NCT04298138), in which nine participants received a subcutaneous inoculation with 0.5 ml of a 1.4 × 103 plaque-forming unit per ml suspension of the attenuated DENV-3 strain CH53489. The primary and secondary endpoints of the study were to assess the safety of this DENV-3 strain in healthy flavivirus-seronegative individuals. All participants developed RNAaemia within 7 days after inoculation with peak titre ranging from 3.13 × 104 to 7.02 × 108 genome equivalents per ml. Solicited symptoms such as fever and rash, clinical laboratory abnormalities such as lymphopenia and thrombocytopenia, and self-reported symptoms such as myalgia were consistent with mild-to-moderate dengue in all volunteers. DENV-3-specific seroconversion and memory T cell responses were observed within 14 days after inoculation as assessed by enzyme-linked immunosorbent assay and interferon-gamma-based enzyme-linked immunospot. RNA sequencing and serum cytokine analysis revealed anti-viral responses that overlapped with the period of viraemia. The magnitude and frequency of clinical and immunologic endpoints correlated with an individual’s peak viral titre.